Brief: Paradigm Biopharmaceuticals Says U.S FDA Cleared IND Application To Proceed With Phase 3 Trial
03/11/2021 01:34
Nov 3 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX :
* U.S FDA CLEARED IND APPLICATION TO PROCEED WITH PHASE 3
TRIAL,
EVALUATING INJECTABLE PENTOSAN POLYSULFATE SODIUM
Source text for Eikon: ID:nASX7wFjTm
Further company coverage: PAR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt